摘要
布格替尼(brigatinib)是第2代间变性淋巴瘤激酶(ALK)酪氨酸激酶抑制剂,通过抑制ALK自身磷酸化和ALK-介导的下游信号蛋白STAT3、AKT、ERK1/2,以及S6在体外和体内的磷酸化,而表现出对4种EML4-ALK的突变体形式的体内抗肿瘤活性。对间变性淋巴瘤激酶转移性非小细胞肺癌(NSCLC)患者有显著疗效。美国食品与药品管理局于2017年4月批准布格替尼上市,本文以布格替尼为关键词进行文献检索,并对其作用机制、药动学、临床评价、用法用量、药物相互作用及安全性等进行综述。
Brigatinib is a second-generation anaplastic lymphoma kinase(ALK) tyrosine kinase inhibitor(TKI). It shows anti-tumor activity of4 kinds of EML4-ALK mutant forms by inhibiting the phosphorylation of ALK and ALK-mediated downstream signaling proteins, STAT3, AKT,ERK1/2. also by inhibiting the phosphorylation of S 6 in vitro and in vivo. It shows a significant curative effect of the anaplastic lymphoma kinase(ALK+) metastatic non-small cell lung cancer(NSCLC) patients. FDA approved brigatinib in April 2017. After literature search for brigatinib with keywords,the mechanism of action, pharmacokinetics, clinical evaluation, dosage, drug interactions, and safety of brigatinibwere reviewed
作者
杨雪
倪倩
裴艺芳
封宇飞
YANG Xue;NI Qian;PEI Yi-fang;FENG Yu-fei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Assessment of Clinical Drugs Risk and Individual Application Key Laboratory,Beijing 100730,China)
出处
《临床药物治疗杂志》
2018年第6期32-36,共5页
Clinical Medication Journal
关键词
布格替尼
间变性淋巴瘤激酶酪氨酸激酶抑制剂
非小细胞肺癌
转移性
药理作用
临床评价
brigatinib
anaplastic lymphoma kinase tyrosine kinase inhibitor (ALK-TKI)
non-small cell lung cancer (NSCLC)
metastatic
phar-macological
clinical evaluation